Unichem Laboratories receives ANDA Approval for Quetiapine Extended-Release Tablets

Unichem Laboratories Limited has received ANDA approval for its Quetiapine Extended-Release Tablets USP, 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg from the United States Food and Drug Administration (USFDA) to market a generic version of SEROQUEL XR® (Quetiapine) Tablet, Extended Release, 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg of AstraZeneca Pharmaceuticals LP.

Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disorder and adjunctive treatment of Major Depressive Disorder (MDD). The product will be commercialized from Unichem's Goa Plant.

Shares of Unichem Laboratories Limited was last trading in BSE at Rs. 279.30 as compared to the previous close of Rs. 273.80. The total number of shares traded during the day was 3913 in over 611 trades.

The stock hit an intraday high of Rs. 282.00 and intraday low of 272.40. The net turnover during the day was Rs. 1077908.00.

Source : Equity Bulls

Keywords

UnichemLaboratories INE351A01035 ANDAApproval USFDA QuetiapineExtendedReleaseTablets